Cargando…

Delayed angioedema after administration of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine

Detalles Bibliográficos
Autores principales:	Watts, Melissa M., Maurer, Laura E., Grammer, Leslie C., Saltoun, Carol A., Stevens, Whitney W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539818/ https://www.ncbi.nlm.nih.gov/pubmed/34699970 http://dx.doi.org/10.1016/j.anai.2021.10.021

Ejemplares similares

M102 A CASE OF DELAYED UVULAR ANGIOEDEMA AFTER ADMINISTRATION OF THE COVID-19 VACCINE
por: Kim, S., et al.
Publicado: (2021)

Asthma Severity and COVID-19 Related Hospitalizations
por: Mambetsariev, Nurbek, et al.
Publicado: (2022)

Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
por: Akamine, Christine M., et al.
Publicado: (2022)

Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
por: Gaebler, Christian, et al.
Publicado: (2022)

Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine( )
por: Maron, Jenny S, et al.
Publicado: (2022)

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination
por: Chen, Xuemin, et al.
Publicado: (2023)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
por: Vanijcharoenkarn, Kristine, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients
por: Strauss, Alexandra T., et al.
Publicado: (2022)

Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older Adults( )
por: Shapiro, Janna R, et al.
Publicado: (2022)

Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 Messenger Ribonucleic Acid Vaccines in Infected Individuals: A Systematic Review
por: Roslan, Madihah, et al.
Publicado: (2023)

Detection of neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines
por: Romano, Ciro, et al.
Publicado: (2021)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Ticagrelor: A Rare, Delayed Case of Angioedema
por: Walia, Jasmit, et al.
Publicado: (2023)

Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation
por: Rocco, Joseph M, et al.
Publicado: (2021)

Bilateral Axillo-Brachial Artery Stenosis Following Messenger Ribonucleic Acid (mRNA) Vaccination Against Severe Acute Respiratory Coronavirus 2 (COVID-19)
por: Güven, Hasan
Publicado: (2023)

COVID-19-Vaccine-Pfizer-BioNTech: Delayed uvular angioedema: case report
Publicado: (2022)

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents
por: Schauer, Jenna, et al.
Publicado: (2021)

Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination( )
por: Haralambieva, Iana H, et al.
Publicado: (2022)

Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France
por: Casenaz, Alice, et al.
Publicado: (2022)

Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report
por: Alebna, Pamela Lamisi, et al.
Publicado: (2023)

Patient‐physician interactions in hereditary angioedema—Key learnings from the coronavirus disease 2019 pandemic
por: Maurer, Marcus, et al.
Publicado: (2023)

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel
por: Swift, Melanie D, et al.
Publicado: (2021)

Facial Angioedema after the first dose of Covishield (adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccine): follow-up after the second and third booster doses
por: Eyer-Silva, Walter de Araujo, et al.
Publicado: (2022)

Threatened Respiratory Compromise in the Setting of Isolated Angioedema
por: Stephenson, Graham S., et al.
Publicado: (2018)

Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
por: Bygum, Anette, et al.
Publicado: (2017)

Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series
por: Peigottu, Maria Francesca, et al.
Publicado: (2021)

Fulminant Myocarditis 24 Days after Coronavirus Disease Messenger Ribonucleic Acid Vaccination
por: Kawano, Hiroaki, et al.
Publicado: (2022)

Acute urticaria with angioedema in the setting of coronavirus disease 2019
por: Adeliño, Raquel, et al.
Publicado: (2020)

Lisinopril: Severe angioedema: case report
Publicado: (2021)

588 Delayed Diagnosis of Hereditary Angioedema. A Case Report
por: González-Díaz, Sandra, et al.
Publicado: (2012)

Efficacy of Messenger RNA–1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021
por: Stephenson, Kathryn E, et al.
Publicado: (2023)

Killing the β-catenin messenger
por: Leslie, Mitch
Publicado: (2009)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents
por: Canaday, David H, et al.
Publicado: (2021)

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
por: Corradini, Paolo, et al.
Publicado: (2022)

Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency
por: Rubinstein, Eitan, et al.
Publicado: (2014)

Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2021)

Acquired Angioedema Acute Attack After Administration of the Moderna COVID-19 (mRNA-1273) Vaccine
por: Graziani, Alessandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pohmdt7k2jfag4495psk6htvme